Clinical Trial: CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897136) titled 'CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia' on Oct. 13.

Brief Summary: This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell injection in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML; acute promyelocytic leukemia excluded). After leukapheresis for CAR-T cell manufacture, participants receive lymphodepleting conditioning (fludarabine 30 mg/m^2/day plus cyclophosphamide 300 mg/m^2/day on Days -5 to -3), followed by a si...